Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07475000

Second Dose of Varicella Vaccine in Healthy Children

Immunogenicity and Safety of the Second Dose of Varicella Vaccine in Healthy Children: An Open-label Study

Status
Recruiting
Phase
Phase 3
Study type
Interventional
Enrollment
300 (estimated)
Sponsor
Sinovac (Dalian) Vaccine Technology Co., Ltd. · Industry
Sex
All
Age
15 Months – 12 Years
Healthy volunteers
Accepted

Summary

This study aim to assess the immunogenicity and safety of interchangeable administration of the second dose of varicella vaccine. A total of 300 healthy participants aged 15 months - 12 years will be enrolled. Written informed consent form will be obtained from participants' parents or legally acceptable representatives (and assents will be obtained from participants aged above 9 years old and written consent forms will be prepared and consent will be obtained in writing if possible from the participants aged 3-8 years old.) before enrollment. Participants will be assigned to 5 groups according to the brand of first dose varicella vaccine they received at the age of 12 months. All participants will receive the second dose of varicella vaccine manufactured by Sinovac. The duration of individual participation from enrollment to the last onsite visit will be a maximum of 42 days. The end of study is considered the completion of the last visit for the last participant in this study. Blood samples (2.5 - 3.0ml per time) for immunogenicity assessment will be collected. The blood samples will be collected before vaccination and 42 days after vaccination.

Conditions

Interventions

TypeNameDescription
BIOLOGICALPROVARIXParticipants will receive one dose (0.5 mL) of PROVARIX (VarV), a live attenuated varicella vaccine manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd., administered as the second dose of varicella vaccination.

Timeline

Start date
2026-01-28
Primary completion
2026-07-15
Completion
2026-11-15
First posted
2026-03-16
Last updated
2026-03-16

Locations

5 sites across 1 country: Turkey (Türkiye)

Source: ClinicalTrials.gov record NCT07475000. Inclusion in this directory is not an endorsement.

Second Dose of Varicella Vaccine in Healthy Children (NCT07475000) · Clinical Trials Directory